Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Receives Consensus Rating of “Hold” from Analysts

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) has been assigned a consensus rating of “Hold” from the twenty brokerages that are currently covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, eleven have given a hold recommendation and seven have given a buy recommendation to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $123.33.

Several research firms have commented on ZBH. Barclays lowered their target price on Zimmer Biomet from $125.00 to $118.00 and set an “underweight” rating on the stock in a research note on Thursday, December 12th. Oppenheimer reduced their target price on shares of Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating for the company in a research report on Tuesday, October 15th. Truist Financial raised their price target on shares of Zimmer Biomet from $117.00 to $118.00 and gave the stock a “hold” rating in a research report on Wednesday, December 18th. Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a report on Thursday, October 31st. Finally, Wells Fargo & Company increased their target price on shares of Zimmer Biomet from $110.00 to $117.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 31st.

Institutional Investors Weigh In On Zimmer Biomet

Several large investors have recently modified their holdings of ZBH. Dunhill Financial LLC boosted its position in shares of Zimmer Biomet by 1,090.0% during the 3rd quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 218 shares in the last quarter. Ashton Thomas Securities LLC bought a new position in shares of Zimmer Biomet during the 3rd quarter worth approximately $28,000. Bangor Savings Bank acquired a new stake in shares of Zimmer Biomet during the 3rd quarter worth approximately $31,000. Brooklyn Investment Group acquired a new stake in shares of Zimmer Biomet during the 3rd quarter worth approximately $35,000. Finally, Quarry LP bought a new stake in shares of Zimmer Biomet in the 2nd quarter valued at $53,000. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Zimmer Biomet Stock Up 2.9 %

Shares of Zimmer Biomet stock opened at $104.47 on Friday. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.70 and a current ratio of 1.36. Zimmer Biomet has a 52-week low of $100.67 and a 52-week high of $133.90. The firm has a market cap of $20.80 billion, a PE ratio of 19.86, a P/E/G ratio of 1.96 and a beta of 1.02. The business’s 50 day simple moving average is $108.03 and its 200 day simple moving average is $108.02.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, meeting the consensus estimate of $1.74. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The company had revenue of $1.82 billion during the quarter, compared to the consensus estimate of $1.80 billion. During the same quarter in the prior year, the firm posted $1.65 EPS. The firm’s revenue for the quarter was up 4.1% compared to the same quarter last year. On average, analysts predict that Zimmer Biomet will post 7.99 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Monday, December 30th will be paid a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 0.92%. The ex-dividend date is Monday, December 30th. Zimmer Biomet’s payout ratio is currently 18.25%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.